Rhinitis medicamentosa – preventable disease-Reference-Cited by-同舟云学术

Rhinitis medicamentosa – preventable disease

Published:2019-11-16 Issue:20 Volume: Page:27-30
ISSN:2658-5790
Container-title:Medical Council
language:
Short-container-title:Medicinskij sovet

Author:

Kryukov A. I.¹^ORCID,Turovskiy A. B.²,Kolbanova I. G.³^ORCID,Musayev K. M.³^ORCID,Karasov A. B.³^ORCID

Affiliation:

1. L.I. Sverzhevsky Research Clinical Institute of Otorhinolaryngology; N.I. Pirogov Russian National Research Medical University

2. L.I. Sverzhevsky Research Clinical Institute of Otorhinolaryngology; V.V. Veresaev Municipal Clinical Hospital

3. L.I. Sverzhevsky Research Clinical Institute of Otorhinolaryngology

Abstract

Aim of the study – analysis of modern ideas about the pathogenesis of rhinitis medicamentosa. The authors consider the factors causing changes in inflammatory nature and leading to rhinitis medicamentosa. The comparative estimation of modern means of pharmacotherapy was made. On the basis of literature and clinical research data, it is concluded that Otrivin has a much more gentle effect and contributes less to the development of rhinitis medicamentosa.

Publisher

Remedium, Ltd.

Subject

General Medicine

Reference10 articles.

1. Wallace D.V., Dykewicz M.S., Bernstein D.I., Blessing-Moore J., Cox L., Khan D.A., Lang D.M., Nicklas R.A., Oppenheimer J., Portnoy J.M., Randolph C.C., Schuller D., Spector S.L., Tilles S.A. Joint Task Force on Practice. American Academy of Allergy. Asthma & Immunology. American College of Allergy. Asthma and Immunology. Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of rhinitis: an updated practice parameter. J. Allergy Clin. Immunol. 2008;122(2 Suppl):1-84. doi:10.1016/j.jaci.2008.06.003.

2. Ramey J.T., Bailen E., Lockey R.F. Rhinitis medicamentosa. J Investig Allergol Clin Immunol. 2006;16(3):148-55. Available at: https://www. ncbi.nlm.nih.gov/pubmed/16784007.

3. Mortuaire G., de Gabory L., François M., Massé G., Bloch F., Brion N., Jankowski R., Serrano E. Rebound congestion and rhinitis medicamentosa: nasal decongestants in clinical practice. Critical review of the literature by a medical panel. Eur Ann Otorhinolaryngol Head Neck Dis. 2013;130(3):137-44. doi: 10.1016/j.anorl.2012.09.005.

4. Graf P. Adverse effects of benzalkonium chloride on the nasal mucosa: allergic rhinitis and rhinitis medicamentosa. Clin Ther. 1999;21(10):1749-55. doi: 10.1016/S0149-2918(99)80053-8.

5. Blue J.A. Rhinitis medicamentosa. Ann Allergy. 1968;26(8):425-9. Available at: https://www.ncbi.nlm.nih.gov/books/NBK538318/.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intranasal drugs possibilities in the treatment of patients with rhinitis medicamentosa;Meditsinskiy sovet = Medical Council;2023-05-10

2. Evaluating the Developed Model of Experimental Rhinitis in Laboratory Rats: Pre-Clinical Experimental Randomized Study;Kuban Scientific Medical Bulletin;2023-02-18

3. Nasal decongestants in the treatment of nasal obstruction;Meditsinskiy sovet = Medical Council;2021-05-12